{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:48:51Z","timestamp":1787312931236,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T00:00:00Z","timestamp":1744761600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NIH","award":["R01AG063913"],"award-info":[{"award-number":["R01AG063913"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>We utilized the Veterans Affairs Healthcare System administrative database to study the clinical decision-making processes for anti-amyloid therapy (AAT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with clinical notes mentioning lecanemab were identified (March 2023\u2013June 2024) for manual review and structured database queries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From an initial sample (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u00a02499), 1064 patients (55,000 notes) were reviewed manually (mean age 76 years; 7.3% women; 9.2% Black; 3.9% Hispanic). The AAT group (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a056) had lower rates of common comorbidities, except post-traumatic stress disorder, than patients excluded from AAT (\n                      <jats:italic>n<\/jats:italic>\n                      \u00a0=\u00a0528). The documented notes including \u201cLack of patient interest\/resource constraints\u201d (24.6% vs 3.6%), \u201canticoagulant use\u201d (23.1% vs 10.7%), and \u201cadvanced AD\u201d (18.6% vs 0), supplied partial explanations on exclusion vs inclusion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Only 5.3% of patients reached the point of care of being a candidate, scheduled for, or receiving AAT infusion. Patient preference and clinician discretion, especially regarding modifiable factors (e.g., medication regimens), appreciably influence the patient journey to AAT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00415-025-13059-3","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T10:44:16Z","timestamp":1744800256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient journey and decision processes for anti-amyloid therapy in Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"272","author":[{"given":"Brant","family":"Mittler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Cambi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Biskach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Reisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Berlowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Morin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald R.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karla","family":"Brandao-Viruet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie J.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Z.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Abbas","family":"Tahami Monfared","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Irizarry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanwu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7463-3295","authenticated-orcid":false,"given":"Weiming","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"13059_CR1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13073-015-0232-5","volume":"7","author":"R Guerreiro","year":"2015","unstructured":"Guerreiro R, Bras J (2015) The age factor in Alzheimer\u2019s disease. Genome Med 7:106. https:\/\/doi.org\/10.1186\/s13073-015-0232-5","journal-title":"Genome Med"},{"key":"13059_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.31887\/DCNS.2009.11.2\/cqiu","volume":"11","author":"C Qiu","year":"2009","unstructured":"Qiu C, Kivipelto M, von Strauss E (2009) Epidemiology of Alzheimer\u2019s disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin Neurosci 11:111\u2013128. https:\/\/doi.org\/10.31887\/DCNS.2009.11.2\/cqiu","journal-title":"Dialogues Clin Neurosci"},{"key":"13059_CR3","first-page":"208","volume":"35","author":"DA Casey","year":"2010","unstructured":"Casey DA, Antimisiaris D, O\u2019Brien J (2010) Drugs for Alzheimer\u2019s disease: are they effective? P T 35:208\u2013211","journal-title":"P T"},{"key":"13059_CR4","unstructured":"Food and Drug Administration (2021) FDA grants accelerated approval for Alzheimer\u2019s drug. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug, Accessed on March 26, 2024"},{"key":"13059_CR5","unstructured":"Food and Drug Administration (2023) FDA grants accelerated approval for Alzheimer\u2019s disease treatment. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment, Accessed on March 26, 2024"},{"key":"13059_CR6","unstructured":"Food and Drug Administration (2024) FDA approves treatment for adults with Alzheimer\u2019s disease. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-approves-treatment-adults-alzheimers-disease. Accessed on November 14, 2024"},{"key":"13059_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, Kanekiyo M, Li D, Reyderman L, Cohen S, Froelich L, Katayama S, Sabbagh M, Vellas B, Watson D, Dhadda S, Irizarry M, Kramer LD, Iwatsubo T (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388:9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"key":"13059_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM, TRAILBLAZER-ALZ 2 Investigators (2023) Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330:512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"key":"13059_CR9","unstructured":"Leqembi [package insert] (2024) Nutley, NJ; Eisai Inc"},{"key":"13059_CR10","unstructured":"Kisunla [package insert] (2024) Indianapolis, IN; Eli Lilly and Company"},{"key":"13059_CR11","unstructured":"U.S. Department of Veterans Affairs (2024) Veterans health administration: about VHA. https:\/\/www.va.gov\/health\/aboutvha.asp Accessed November 14, 2024"},{"key":"13059_CR12","unstructured":"PR Newswire (2023) US Veteran\u2019s Health Administration (VA) provides coverage of LEQEMBITM (lecanemab-IRMB) two months after Lequmbi\u2019s FDA acceleated approval for veterans living with early stages of Alzheimer\u2019s disease. https:\/\/www.prnewswire.com\/news-releases\/us-veterans-health-administration-vha-provides-coverage-of-leqembi-lecanemab-irmb-two-months-after-leqembis-fda-accelerated-approval-for-veterans-living-with-early-stages-of-alzheimers-disease-301770531.html Accessed November 14, 2024"},{"key":"13059_CR13","unstructured":"Veterans Affairs Pharmacy Benefits Management Services (2023) Lecanemab-irmb (LEQEMBI) National Drug Monograph. https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/MON_Lecanemab-irmb_LEQEMBI_monograph.pdf Accessed November 14, 2024"},{"key":"13059_CR14","unstructured":"Food and Drug Administration (2023) FDA converts novel Alzheimer\u2019s disease treatment to traditional approval. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-converts-novel-alzheimers-disease-treatment-traditional-approval, Accessed November 14, 2024"},{"key":"13059_CR15","unstructured":"Veterans Affairs Pharmacy Benefits Management Services (2023) Lecanemab-irmb (LEQEMBI) Criteria for Use. https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/CFU_Lecanemab-irmb_LEQEMBI_CFU_rev2_Aug_2023.pdf Accessed July 1, 2024"},{"key":"13059_CR16","unstructured":"Veterans Affairs Pharmacy Benefits Management Services (2024) Lecanemab-irmb (LEQEMBI) criteria for use. https:\/\/www.va.gov\/formularyadvisor\/DOC_PDF\/CFU_Lecanemab-irmb_LEQEMBI_CFU_Aug_2024.pdf Accessed November 14, 2024"},{"key":"13059_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.14283\/jpad.2023.30","volume":"10","author":"J Cummings","year":"2023","unstructured":"Cummings J, Apostolova L, Rabinovici GD, Atri A, Aisen P, Greenberg S, Hendrix S, Selkoe D, Weiner M, Petersen RC, Salloway S (2023) Lecanemab: appropriate use recommendations. J Prev Alzheimers Dis 10:362\u2013377. https:\/\/doi.org\/10.14283\/jpad.2023.30","journal-title":"J Prev Alzheimers Dis"},{"key":"13059_CR18","doi-asserted-by":"publisher","first-page":"e1837","DOI":"10.1212\/WNL.0000000000207770","volume":"101","author":"RR Pittock","year":"2023","unstructured":"Pittock RR, Aakre JA, Castillo AM, Ramanan VK, Kremers WK, Jack CR Jr, Vemuri P, Lowe VJ, Knopman DS, Petersen RC, Graff-Radford J, Vassilaki M (2023) Eligibility for anti-amyloid treatment in a population-based study of cognitive aging. Neurology 101:e1837\u2013e1849. https:\/\/doi.org\/10.1212\/WNL.0000000000207770","journal-title":"Neurology"},{"key":"13059_CR19","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.4283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, Freeman SW, Cain JF, Shang WY, Wasz KM, Orr AT, Shields CB, Barve SS, Pugh KG (2024) Initial experience with Lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis 11:1549\u20131562. https:\/\/doi.org\/10.4283\/jpad.2024.159","journal-title":"J Prev Alzheimers Dis"},{"key":"13059_CR20","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/aje\/kwq433","volume":"173","author":"H Quan","year":"2011","unstructured":"Quan H, Li B, Couris CM, Fushimi K, Graham P, Hider P, Januel JM, Sundararajan V (2011) Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 173:676\u2013682. https:\/\/doi.org\/10.1093\/aje\/kwq433","journal-title":"Am J Epidemiol"},{"key":"13059_CR21","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1007\/s40120-023-00540-2","volume":"12","author":"BJ Aguilar","year":"2023","unstructured":"Aguilar BJ, Miller D, Jasuja G, Li X, Shishova E, O\u2019Connor MK, Nguyen A, Morin P, Berlowitz D, Zhang R, Monfared AAT, Zhang Q, Xia W (2023) Rule-based identification of individuals with mild cognitive impairment or Alzheimer\u2019s disease using clinical notes from the United States Veterans Affairs Healthcare System. Neurol Ther 12:2067\u20132078. https:\/\/doi.org\/10.1007\/s40120-023-00540-2","journal-title":"Neurol Ther"},{"key":"13059_CR22","doi-asserted-by":"crossref","unstructured":"Honig L, Bell K, Gonzalez W, Dimuro J, Kim M, Jagannathan R< Noble J, Marder K, Mayeux R (2024) Lecanemab use in clinical practice at an academic medical center. In: The 17th annual clinical trials on Alzheimer\u2019s disease (CTAD) conference; Madrid, Spain.","DOI":"10.1002\/alz.095181"},{"key":"13059_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282071","volume":"18","author":"M Shepherd-Banigan","year":"2023","unstructured":"Shepherd-Banigan M, Miller KEM, Hastings SN, Schleiden LJ, Thorpe JM (2023) Use of high cost care among Veterans with comorbid mental illness and Alzheimer\u2019s disease and related dementias. PLoS ONE 18:e0282071. https:\/\/doi.org\/10.1371\/journal.pone.0282071","journal-title":"PLoS ONE"},{"key":"13059_CR24","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1093\/milmed\/usae161","volume":"189","author":"MK O'Connor","year":"2024","unstructured":"O\u2019Connor MK, Aguilar BJ, Nguyen A, Berlowitz D, Zhang R, Tahami Monfared AA, Zhang Q, Xia W (2024) The role of mental health conditions in early detection and treatment of veterans with Alzheimer\u2019s dementia. Mil Med 189:1409\u20131413. https:\/\/doi.org\/10.1093\/milmed\/usae161","journal-title":"Mil Med"},{"key":"13059_CR25","unstructured":"Sabbagh M, Zhao C, Mahendran M, Ryeong Jang S, Laliberte F, Zhang K, Frech F, Nair KV (2024) Lecanemab treatment in real world settings in the United States. In: The 17th annual clinical trials on Alzheimer\u2019s disease (CTAD) conference; Madrid, Spain"},{"key":"13059_CR26","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1212\/WNL.0000000000207757","volume":"101","author":"VK Ramanan","year":"2023","unstructured":"Ramanan VK, Armstrong MJ, Choudhury P, Coerver KA, Hamilton RH, Klein BC, Wolk DA, Wessels SR, Jones LK, AAN Quality Committee (2023) Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology. Neurology 101:842\u2013852. https:\/\/doi.org\/10.1212\/WNL.0000000000207757","journal-title":"Neurology"},{"key":"13059_CR27","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/alz.12476","volume":"18","author":"E Jutkowitz","year":"2022","unstructured":"Jutkowitz E, Halladay C, Tsai J, Hooshyar D, Quach L, O\u2019Toole T, Rudolph JL (2022) Prevalence of Alzheimer\u2019s disease and related dementias among veterans experiencing housing insecurity. Alzheimers Dement 18:1306\u20131313. https:\/\/doi.org\/10.1002\/alz.12476","journal-title":"Alzheimers Dement"},{"key":"13059_CR28","first-page":"40","volume":"33","author":"J Guzman-Clark","year":"2016","unstructured":"Guzman-Clark J, Harrell K, Leff A, Henriques D, Ines E, Rofail M, Knapp H, Castle S (2016) Implementation of an ECHO-based program to provide geriatric specialty care consultation and education to remote primary care teams. Fed Pract 33:40\u201345","journal-title":"Fed Pract"},{"key":"13059_CR29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/ppar\/prz030","volume":"30","author":"HD Lum","year":"2020","unstructured":"Lum HD, Nearing K, Pimentel CB, Levy CR, Hung WW (2020) Anywhere to anywhere: use of telehealth to increase health care access for older, rural veterans. Public Policy Aging Rep 30:12\u201318. https:\/\/doi.org\/10.1093\/ppar\/prz030","journal-title":"Public Policy Aging Rep"},{"key":"13059_CR30","first-page":"36","volume":"31","author":"LR Moo","year":"2014","unstructured":"Moo LR, Jafri Z, Morin PJ (2014) Home-based video telehealth for veterans with dementia. Fed Pract 31:36\u201338","journal-title":"Fed Pract"},{"key":"13059_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/geriatrics3020029","volume":"3","author":"JS Powers","year":"2018","unstructured":"Powers JS, Buckner J (2018) Reaching out to rural caregivers and veterans with dementia utilizing clinical video-telehealth. Geriatrics (Basel) 3:29. https:\/\/doi.org\/10.3390\/geriatrics3020029","journal-title":"Geriatrics (Basel)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13059-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13059-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T08:41:37Z","timestamp":1747644097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13059-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["13059"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13059-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,16]]},"assertion":[{"value":"6 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Amir Abbas Tahami Monfared, Michael Irizzary, and Quanwu Zhang are employees of Eisai Inc. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All clinical notes from the nationwide VAHS database electronic health records (EHR) were searched, and the study was approved by the Bedford VA Healthcare System Institutional Review Board (IRB). Consent was not required for database analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"341"}}